LACTOLOGY FOUNDATION

Clobenzorex (ATC A08AA08) During Lactation

Clobenzorex is a centrally acting anorectic and sympathomimetic agent classified as ATC A08AA08. Because it is metabolized to amphetamine and no adequate human milk-transfer or infant-outcome data are available, its use is generally not recommended during breastfeeding; non-stimulant weight-management approaches should be preferred.academic.oup+2

ATC class and general pharmacology

ATC code: A08AA08
ATC group: A08A — Antiobesity preparations, excluding diet products
Pharmacological subgroup: A08AA — Centrally acting antiobesity products
International nonproprietary name: Clobenzorex

Clobenzorex is an amphetamine-related phenethylamine derivative used in certain countries as a short-term adjunct to dietary intervention and physical activity in the management of obesity. It is a centrally acting appetite suppressant with sympathomimetic stimulant properties. Its clinical use must be understood within the context of the limited long-term efficacy and substantial adverse-effect potential shared by older stimulant anorectics.

Pharmacologically, clobenzorex acts substantially as a prodrug of amphetamine. After oral administration, it undergoes biotransformation to several metabolites, including 4-hydroxyclobenzorex and amphetamine. The formation of amphetamine is toxicologically and lactologically important, because amphetamine has clinically relevant central nervous system and cardiovascular stimulant activity. Controlled toxicological studies have shown that amphetamine and 4-hydroxyclobenzorex may remain detectable after the parent compound is no longer detectable, demonstrating that exposure cannot be assessed solely by measuring clobenzorex itself.academic.oup+1

The anorectic effect is presumed to arise primarily from enhanced central monoaminergic signalling, particularly catecholaminergic neurotransmission. This produces appetite suppression but can also cause stimulation, insomnia, nervousness, increased heart rate, and increased blood pressure. In experimental behavioural models, clobenzorex has demonstrated amphetamine-like effects, albeit at substantially lower potency than (+)-amphetamine.europepmc+1

Toxicological profile

The toxicological profile of clobenzorex is shaped by both the parent drug and its active amphetamine-related metabolites. It should therefore be assessed as an amphetamine-prodrug exposure rather than as an isolated anti-obesity medicine.

Potential adverse effects in adults include:

• Insomnia, restlessness, nervousness, anxiety, irritability, tremor, and headache.
• Reduced appetite, dry mouth, nausea, abdominal discomfort, and constipation.
• Tachycardia, palpitations, elevated blood pressure, and other sympathomimetic cardiovascular effects.
• Aggravation of pre-existing anxiety, agitation, psychosis, or other psychiatric vulnerability.
• Potential for tolerance, misuse, dependence, and withdrawal-related symptoms.
• Positive amphetamine toxicology results, which may require specialized metabolite testing to distinguish prescribed clobenzorex use from direct amphetamine exposure.academic.oup+1

The presence of amphetamine as a metabolite is especially important in overdose or repeated administration. Maternal toxicity may involve pronounced psychomotor agitation, insomnia, hypertension, tachyarrhythmia, hyperthermia, confusion, and, in severe cases, seizures or cardiovascular complications. The risk may increase when clobenzorex is combined with other stimulants, high caffeine intake, decongestants with sympathomimetic activity, serotonergic medicines, or monoamine oxidase inhibitors.

Clobenzorex should be avoided or used only under specialist supervision in individuals with clinically significant cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, severe anxiety states, psychotic disorders, a history of substance-use disorder, or concurrent exposure to other stimulants. In a lactating person, these maternal risks are compounded by potential infant exposure and by the possibility of impaired milk production.

Lactation pharmacology and infant exposure

There are no robust published studies adequately quantifying clobenzorex concentrations in human milk, milk-to-plasma ratios, relative infant dose, infant plasma concentrations, or developmental outcomes in breastfed infants. Therefore, a numerical relative infant dose cannot be responsibly calculated for clobenzorex.

Nevertheless, the pharmacological properties of clobenzorex support a precautionary assessment:

• Clobenzorex is an amphetamine-related, centrally active, low-molecular-weight stimulant.
• It is metabolized to amphetamine, an active compound of specific concern in lactation.
• Maternal systemic exposure involves not only the parent medicine but also metabolites that may persist longer than the parent compound.
• The absence of milk data does not establish safety; it creates substantial uncertainty regarding both the magnitude and duration of infant exposure.academic.oup+1

Amphetamine-class substances may enter breast milk, and infant susceptibility is greatest in neonates, preterm infants, medically fragile infants, and infants with reduced hepatic or renal clearance. Information from LactMed on methamphetamine demonstrates that both methamphetamine and amphetamine can be detected in breast milk and infant serum following maternal use, reinforcing the biological plausibility of milk transfer for amphetamine-related exposures. Although this evidence cannot be directly converted into a dose estimate for clobenzorex, it supports a conservative approach.ncbi.nlm.nih

Potential manifestations of stimulant exposure in a breastfed infant could include:

• Irritability, unusual wakefulness, disturbed sleep, or excessive crying.
• Tremor, jitteriness, hypertonia, or increased startle response.
• Poor feeding, reduced weight gain, vomiting, or gastrointestinal disturbance.
• Tachycardia, sweating, elevated blood pressure, or other signs of sympathetic stimulation.
• In severe exposures, altered neurological status or seizures.

In addition to direct drug transfer, maternal sympathomimetic stimulation may interfere with breastfeeding indirectly. Appetite suppression, insomnia, anxiety, dehydration, reduced caloric intake, and diminished maternal wellbeing may impair lactation performance. Dopaminergic stimulation is also theoretically relevant because dopamine suppresses prolactin secretion; however, the magnitude of any clobenzorex-specific effect on milk production has not been established clinically.

Lactological safety assessment and clinical recommendations

Overall lactological assessment: Avoid during breastfeeding whenever possible.

Clobenzorex should not be considered a preferred or routine option for weight management in lactating women. The principal reasons are the absence of direct human lactation data, its conversion to amphetamine, the potential for infant neurobehavioral and cardiovascular stimulation, the potential for maternal adverse effects, and the availability of safer non-pharmacological strategies during the postpartum period. The ATC classification identifies clobenzorex as a centrally acting anti-obesity agent, while pharmacokinetic evidence confirms formation of amphetamine and persistent metabolites.academic.oup+2

Clinical recommendations

1. Avoid initiation during breastfeeding.
   Do not begin clobenzorex for postpartum weight reduction while the infant receives breast milk, particularly during exclusive breastfeeding.
2. Prefer non-drug management.
   Use individualized nutritional counselling, gradual calorie adjustment compatible with lactation, physical activity appropriate to postpartum recovery, sleep optimization where feasible, and treatment of contributing endocrine or metabolic conditions.
3. Seek specialist review if exposure occurs.
   A lactating patient already receiving clobenzorex should contact the prescribing clinician, paediatrician, and a specialist medicines-in-lactation or clinical toxicology service promptly. The clinical decision should account for dose, timing, duration, formulation, co-medications, maternal symptoms, infant age, prematurity, and the proportion of feeding supplied by breast milk.
4. Do not rely on timing feeds alone.
   Because clobenzorex produces active metabolites, including amphetamine, and because metabolite persistence may exceed that of the parent drug, simply breastfeeding immediately before a dose or discarding one feed is not a dependable strategy to eliminate infant exposure.academic.oup+1
5. Consider temporary interruption only under individualized advice.
   If clinically important maternal exposure has occurred, decisions regarding temporary breastfeeding interruption, milk expression and disposal, and the timing of resumption should be individualized by clinicians. The mother should generally maintain milk removal if breastfeeding is interrupted, where medically appropriate, to reduce engorgement, mastitis risk, and loss of milk production.
6. Monitor the infant after known exposure.
   Clinical monitoring should include feeding effectiveness, sleep pattern, irritability, tremor, heart rate, weight trajectory, and signs of dehydration. Urgent medical assessment is appropriate if the infant develops marked agitation, poor feeding, persistent vomiting, abnormal movements, lethargy, breathing difficulty, fever, or suspected cardiovascular symptoms.
7. Avoid co-exposures.
   Concurrent use of other stimulants, illicit amphetamines, excessive caffeine, nicotine, sympathomimetic decongestants, or psychoactive substances may increase maternal and infant risk and makes clinical interpretation more difficult.